Study for Chinese medicine Yiqi Huoxue Huaji decoction anti hepatitis B related liver cirrhosis based on multi-omics technology
- Conditions
- Hepatitis B related liver cirrhosis
- Registration Number
- ITMCTR2000003979
- Lead Sponsor
- Shenzhen Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria of traditional Chinese and Western medicine for severe liver fibrosis of hepatitis B in this study;
2. Aged 18-65 years old, without heart, brain, kidney and other diseases;
3. Those who are informed about this research, volunteer to take the test and sign the informed consent.
1. Those who do not meet the diagnostic criteria of this study;
2. Those younger than 18 years old or above 65 years old;
3. Combined with alcoholic liver disease, non-alcoholic fatty liver disease, other viral hepatitis, autoimmune liver disease, parasitic disease and other specific liver diseases that can lead to cirrhosis;
4. Combined with severe primary diseases such as cardiovascular, brain, kidney, blood system and endocrine metabolism;
5. Pregnant or breastfeeding women;
6. Those who are known to have a history of allergies to the constituents of the research drug.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AFP;Serum HBV-DNA;Serum ALT;Fibroscan;Serum HBeAg;MicroRNA;Inflammation grade;Color Doppler ultrasound examination;Serum HBsAg;Fibrosis staging;
- Secondary Outcome Measures
Name Time Method